While brachytherapy improved progression-free survival in men with prostate cancer, compared with traditional readiotherapy, the study found that overall survival was not very different between the 2 groups.
A prostate cancer treatment using permanently implanted radioactive “seeds” doubles rates of 5-year tumour-free survival compared with conventional high-dose radiotherapy, a study has found.
Low-dose-rate prostate brachytherapy (LDR-PB) involves the insertion of tiny radioactive implants into the prostate gland. A trial comparing the treatment with dose-escalated external beam radiotherapy found that it was much more successful at banishing cancer. Men who underwent LDR-PB were twice as likely to be cancer-free 5 years later. Scientists studied 398 men with cancer that had not spread outside the prostate gland who were judged to be at high risk of treatment failure based on standard test results.
Lead researcher Professor James Morris, from Vancouver Cancer Centre in Canada, said: “At five years follow-up, we saw a large advantage in progression-free survival in the LDR-PB group.
Link to the complete article on The Guardian: http://bit.ly/1EciTDF
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More